ReviewArthritis research2001
Anti-cytokine therapy in chronic destructive arthritis.
Review in Arthritis research, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 114 citations in OpenAlex.
- Jellyfish collagen ameliorates collagen-induced arthritis CIA in Sprague Dawley rats by modulating inflammatory mediators by inhibiting the NF κB and JAK STAT pathways.Open veterinary journal · 2025Article
- Article
- Serum cytokines in periodontal diseases.Periodontology 2000 · 2025Review
- Article
- Cartilage tissue engineering: From proinflammatory and anti‑inflammatory cytokines to osteoarthritis treatments (Review).Molecular medicine reports · 2022Review
- Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response.Frontiers in immunology · 2021Review
- Joint hemorrhage accelerates cartilage degeneration in a rat immobilized knee model.BMC musculoskeletal disorders · 2020Article
- Molecular mechanism of action and pharmacokinetic properties of methotrexate.Molecular biology reports · 2020Review
- The effect of Ganoderma lucidum extract on immunological function and identify its anti-tumor immunostimulatory activity based on the biological network.Scientific reports · 2018Article
- IL-20 bone diseases involvement and therapeutic target potential.Journal of biomedical science · 2018Review
- A Single Codon Optimization Enhances Recombinant Human TNF-BioMed research international · 2018Article
- N-(2-Hydroxyphenyl)acetamide: a Novel Suppressor of RANK/RANKL Pathway in Collagen-Induced Arthritis Model in Rats.Inflammation · 2017Article
- Nanomaterials in the Context of Type 2 Immune Responses-Fears and Potentials.Frontiers in immunology · 2017Review
- Extracts of Bauhinia championii (Benth.) Benth. attenuate the inflammatory response in a rat model of collagen-induced arthritis.Molecular medicine reports · 2016Article
- K/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory Arthritis.Frontiers in immunology · 2016Review
- Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis.BMC musculoskeletal disorders · 2014Article
- Article
- Effect of Bizhongxiao decoction and its dismantled formulae on IL-1 and TNF levels in collagen-induced arthritis in rat synovial joints.Theoretical biology & medical modelling · 2012Article
- The anti-arthritic and anti-oxidative effect of NBD (6-nitro-1,3-benzodioxane) in adjuvant-induced arthritis (AIA) in rats.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2012Article
- JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis.The American journal of pathology · 2011Article
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor (TNF) and interleukin-1 (IL-1) are considered to be master cytokines in chronic, destructive arthritis. Therapeutic approaches in rheumatoid arthritis (RA) patients have so far focused mainly on TNF, which is a major inflammatory mediator in RA and a potent inducer of IL-1; anti-TNF therapy shows great efficacy in RA patients. However, it is not effective in all patients, nor does it fully control the arthritic process in affected joints of good responders. Directed therapy for IL-1, with IL-1 receptor antagonist, mainly reduces erosions and is marginally anti-inflammatory. It is as yet unclear whether the limited effect is akin to the RA process or linked to suboptimal blocking of IL-1. Analysis of cytokine patterns in early synovial biopsies of RA patients reveals a marked heterogeneity, with variable staining of TNF and IL-1 beta, indicative of TNF-independent IL-1 production in at least some patients. Evidence for this pathway emerged from experimental arthritises in rodents, and is summarized in this review. If elements of the models apply to the arthritic process in RA patients, it is necessary to block IL-1 beta in addition to TNF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.